The Chemours Company (NYSE:CC) Position Increased by GAMMA Investing LLC

GAMMA Investing LLC raised its position in The Chemours Company (NYSE:CC) by 99.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,532 shares of the specialty chemicals company’s stock after purchasing an additional 765 shares during the quarter. GAMMA Investing LLC’s holdings in Chemours were worth $26,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of CC. FMR LLC raised its holdings in shares of Chemours by 3.5% during the 3rd quarter. FMR LLC now owns 18,142,202 shares of the specialty chemicals company’s stock valued at $368,650,000 after purchasing an additional 618,361 shares in the last quarter. Marshall Wace LLP increased its position in Chemours by 23.8% during the second quarter. Marshall Wace LLP now owns 7,009,868 shares of the specialty chemicals company’s stock worth $158,213,000 after buying an additional 1,347,710 shares during the last quarter. Khrom Capital Management LLC raised its holdings in Chemours by 54.6% during the second quarter. Khrom Capital Management LLC now owns 3,456,626 shares of the specialty chemicals company’s stock valued at $78,016,000 after buying an additional 1,220,967 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Chemours by 1.2% in the third quarter. Geode Capital Management LLC now owns 2,491,748 shares of the specialty chemicals company’s stock worth $50,646,000 after buying an additional 28,803 shares during the last quarter. Finally, Appian Way Asset Management LP acquired a new stake in shares of Chemours in the third quarter worth about $34,151,000. 76.26% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Chemours

In related news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $20.64, for a total value of $154,800.00. Following the completion of the transaction, the senior vice president now owns 16,645 shares of the company’s stock, valued at $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.47% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

CC has been the topic of a number of recent analyst reports. Mizuho cut their price objective on Chemours from $22.00 to $21.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 7th. The Goldman Sachs Group dropped their price target on shares of Chemours from $24.00 to $21.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 7th. Morgan Stanley decreased their price objective on shares of Chemours from $25.00 to $22.00 and set an “equal weight” rating for the company in a report on Monday. Barclays raised their target price on shares of Chemours from $21.00 to $23.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $25.00 target price on shares of Chemours in a research report on Thursday, December 12th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $23.75.

Chemours Price Performance

NYSE:CC opened at $18.79 on Thursday. The company has a debt-to-equity ratio of 6.05, a current ratio of 1.73 and a quick ratio of 0.92. The Chemours Company has a one year low of $15.10 and a one year high of $32.48. The company has a fifty day moving average price of $19.21 and a 200 day moving average price of $19.80. The stock has a market cap of $2.81 billion, a P/E ratio of 37.58 and a beta of 1.83.

Chemours (NYSE:CC) last announced its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.08. Chemours had a net margin of 1.34% and a return on equity of 29.48%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.44 billion. During the same quarter in the prior year, the business earned $0.64 earnings per share. The firm’s revenue for the quarter was up .9% on a year-over-year basis. Analysts anticipate that The Chemours Company will post 1.35 earnings per share for the current year.

Chemours Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Friday, November 15th were given a $0.25 dividend. The ex-dividend date of this dividend was Friday, November 15th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 5.32%. Chemours’s dividend payout ratio is currently 200.00%.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.